Psoriasis Trial, Recruiting (NCT07256015)

Psoriasis Trial, Recruiting NCT07256015 Sponsor: Bristol-Myers Squibb Condition: Psoriasis

Printed from Voxsanity (voxsanity.com.au) — NCT07256015 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Psoriasis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have moderate to severe plaque psoriasis
People who started treatment with the medication deucravacitinib (taken on its own, not combined with other treatments) between 4 and 8 weeks before joining, as part of their normal medical care and in line with the reimbursement rules set by the Italian medicines authority (AIFA)
People who have signed a form confirming they understand and agree to take part in the study

Who may not be able to join:

People who are already taking part in another clinical trial for their moderate to severe psoriasis
People who are not able to understand the purpose of the study or are not able to understand and sign the consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bristol Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07256015

Sponsor: Bristol-Myers Squibb

Phase: Not Applicable

Status: Recruiting

Condition: Psoriasis

Trial contact: 855-907-3286

More information: https://clinicaltrials.gov/study/NCT07256015

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have moderate to severe plaque psoriasis
People who started treatment with the medication deucravacitinib (taken on its own, not combined with other treatments) between 4 and 8 weeks before joining, as part of their normal medical care and in line with the reimbursement rules set by the Italian medicines authority (AIFA)
People who have signed a form confirming they understand and agree to take part in the study

Who may not be able to join:

People who are already taking part in another clinical trial for their moderate to severe psoriasis
People who are not able to understand the purpose of the study or are not able to understand and sign the consent form

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Bristol-Myers Squibb

Registry

ClinicalTrials.gov

Start date

5 August 2025

Est. completion

5 July 2027

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

The percentage of participants still receiving deucravacitinib treatment; Absolute Psoriasis Area and Severity Index (PASI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov